Recent advances in genome editing technologies have shown impressive results in genetic disorders, infectious diseases, and cancer, with clinical trials underway. However, translating these technologies to address public health needs has been hindered by challenges such as inadequate integration of research results into pharmaceutical company development strategies and the absence of established standards for acceptable risk-benefit ratios. To cover this gap and thanks to the COST a European funding framework the GenE-HumDi COST action linked together various stakeholders, including pharmaceutical companies, academic institutions, regulatory bodies, patient advocacy associations, and information technology, to address knowledge fragmentation and to accelerate the translation of genome editing technologies for the treatment of human diseases.   During the 12th Biennial Congress of the Sociedad Española de Terapia Génica y Celular we will present the main objectives of GenE-HumDi COST which are to establish a network of GE researchers from various fields to facilitate clinical translation of such technologies. To ensure safety, standardized procedures for assessing the effects of GE. We also aim to coordinate and share scientific knowledge about GE delivery methods, in order to increase project success rates and promote collaboration among basic, translational, regulatory, and clinical experts through scientific meetings. Research training is one of our main activities through the organization of several training schools and short-term scientific missions.  We also aim to disseminate research findings to the public and promote societal discourse around genome editing. Finally, our communication with policymakers will promote safe and efficient biomedical research in genome editing